An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

CKD-501 0.5mg

0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)

DRUG

Placebo

Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks

Trial Locations (9)

Unknown

The Inje University Busan-Paik Hospital, Busan

Soon Chun Hyang University Cheonan Hospital, Cheonan

The Hanyang University Medical Center, Gyeonggi-do

Wonju Severance Christian Hospital, Kangwon-Do

The Hallym University Medical Center, Seoul

The Inje University Sanggye-Paik Hospital, Seoul

The Korea University Anam Hospital, Seoul

The Kyung Hee University Medical Center, Seoul

The Seoul National University Bundang Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY